Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2026)

Janux Therapeutics (JANX) has reported Cash & Equivalents for 7 consecutive years, with $51.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 29.72% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $51.8 million (down 29.72% YoY), while the FY2025 annual figure was $52.3 million, down 87.85% from the prior year.
• Cash & Equivalents slipped to $51.8 million in Q1 2026 per JANX's latest filing, from $52.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $430.6 million in Q4 2024 and bottomed at $14.7 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $76.1 million across 5 years, with a median of $51.8 million in 2026.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 2142.15% — and 2025, when it tumbled 87.85%.
• Janux Therapeutics' Cash & Equivalents stood at $51.4 million in 2022, then plunged by 62.66% to $19.2 million in 2023, then surged by 2142.15% to $430.6 million in 2024, then sank by 87.85% to $52.3 million in 2025, then retreated by 0.97% to $51.8 million in 2026.
• Business Quant data shows JANX's Cash & Equivalents at $51.8 million in Q1 2026, $52.3 million in Q4 2025, and $48.4 million in Q3 2025.